Jack Ingham
Impact in
- Infectious Diseases top 2%
- COVID-19 Clinical Research Studies
- SARS-CoV-2 and COVID-19 Research
-
- Antibiotic Use and Resistance
Papers in
-
- COVID-19 Clinical Research Studies 7
-
- Cell Adhesion Molecules Research 1
- Partner nations
- United KingdomVietnamUnited States
In The Last Decade
Jack Ingham
8 papers receiving 1.7k citations
Jack Ingham's Hit Papers
Peers
Comparison fields: 5 of 89
- Infectious Diseases 1.3k
- Applied Microbiology and Biotechnology 35
- Internal Medicine 27
- Oncology 92
- Statistics and Probability 45
Countries citing papers authored by Jack Ingham
This map shows the geographic impact of Jack Ingham's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jack Ingham with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jack Ingham more than expected).
Fields of papers citing papers by Jack Ingham
This network shows the impact of papers produced by Jack Ingham. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jack Ingham. The network helps show where Jack Ingham may publish in the future.
No co-authors to show.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2021 | 411 |
| 2 | Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial Hit paper breakdown → | 2021 | 393 |
| 3 | Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2022 | 282 |
| 4 | Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis Hit paper breakdown → | 2022 | 231 |
| 5 | 2021 | 213 | |
| 6 | 2022 | 128 | |
| 7 | Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2023 | 84 |
| 8 | 2020 | 2 |
About Jack Ingham
Jack Ingham is a scholar working on Infectious Diseases, Immunology and Allergy, Cell Biology, Molecular Biology and Nuclear Energy and Engineering, having authored 8 papers that have together received 1.7k indexed citations. Recurring topics across this work include COVID-19 Clinical Research Studies (7 papers), Cell Adhesion Molecules Research (1 paper), Skin and Cellular Biology Research (1 paper) and Bioinformatics and Genomic Networks (1 paper). The work is most often cited by research in Infectious Diseases (1.3k citations), Applied Microbiology and Biotechnology (35 citations), Internal Medicine (27 citations), Oncology (92 citations) and Statistics and Probability (45 citations). Jack Ingham has collaborated with scholars based in United Kingdom, Vietnam and United States. Their work appears in journals such as The Lancet, Emergency Medicine Journal and Science Advances.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.